Eli Lilly and Company Revenue for the Trailing 12 Months (TTM) ending March 31, 2025: USD 49.00 B

Eli Lilly and Company Revenue is USD 49.00 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 36.38% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Eli Lilly and Company Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 35.93 B, a 29.76% change year over year.
  • Eli Lilly and Company Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 27.69 B, a -5.56% change year over year.
  • Eli Lilly and Company Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 29.32 B, a 15.06% change year over year.
  • Eli Lilly and Company Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 25.49 B, a 10.39% change year over year.
Key Data
Date Revenue Revenue Gross Profit Operating Income